Hyodeoxycholic acid

Drug Profile

Hyodeoxycholic acid

Alternative Names: AHRO-001; HDCA

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AtheroNova
  • Developer AtheroNova; CardioNova
  • Class Antihyperlipidaemics; Cholic acids; Small molecules; Vascular disorder therapies
  • Mechanism of Action Cholesterol absorption inhibitors; Gene expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atherosclerosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Atherosclerosis(In volunteers) in Russia (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO, Tablet)
  • 30 Jul 2014 AtheroNova initiates the phase Ib portion of a trial in Atherosclerosis (in volunteers) in Russia (NCT01931241; 9166319)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top